(4R)-4-aminoisoxazolidin-3-one; 2-ethylpyridine-4-carbothioamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4R)-4-aminoisoxazolidin-3-one; 2-ethylpyridine-4-carbothioamide
• 英文别名: (4R)-4-amino-1,2-oxazolidin-3-one;2-ethylpyridine-4-carbothioamide
• 化学式: C11H16N4O2S
• 分子量: 268.34
• InChiKey: HXPKIKQRQZWSBE-ARGLLVQISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.04
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  102
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• TREATMENT OF EVOLVING BACTERIAL RESISTANCE DISEASES INCLUDING KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE
  申请人：Your Energy Systems, LLC

  公开号：EP2956153A1

  公开（公告）日：2015-12-23
• TREATMENT OF MULTIPLE EVOLVING BACTERIAL RESISTANCE DISEASES WITH LIPOSOMALLY FORMULATED GLUTATHIONE
  申请人：CHILDREN'S HEALTHCARE OF ATLANTA, INC.

  公开号：US20160158308A1

  公开（公告）日：2016-06-09

  The invention proposes routine treatment of patients, particularly those admitted to an ICU, with Vitamin D and liposomal glutathione for prophylaxis and treatment against Group B Streptococcus and Carbapenem-resistant enterobacteriaceae, and biomarkers to measure effectiveness of treatment. Further, because the method of treatment bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more antibiotic- and/or carbapenem resistant strains is downgraded.
• US9913801B2
  申请人：——

  公开号：US9913801B2

  公开（公告）日：2018-03-13
• [EN] TREATMENT OF EVOLVING BACTERIAL RESISTANCE DISEASES INCLUDING KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE<br/>[FR] TRAITEMENT DE MALADIES DE RÉSISTANCE BACTÉRIENNE ÉVOLUTIVE COMPRENANT KLEBSIELLA PNEUMONIAE AVEC DU GLUTATHION FORMULÉ DANS DES LIPOSOMES
  申请人：GUILFORD FREDERICK TIMOTHY

  公开号：WO2014126594A1

  公开（公告）日：2014-08-21

  The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.
• [EN] TREATMENT OF KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE<br/>[FR] TRAITEMENT DE KLEBSIELLE PNEUMONIAE AVEC DU GLUTATHION LIPOSOMIQUE
  申请人：BROWN LOU ANN

  公开号：WO2015073077A1

  公开（公告）日：2015-05-21

  The invention proposes routine treatment of patients, particularly those admitted to an ICU, with Vitamin D and liposomal glutathione for prophylaxis and treatment against Group B Streptococcus and Carbapenem-resistant enterobacteriaceae, and biomarkers to measure effectiveness of treatment. Further, because the method of treatment bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more antibiotic- and/or carbapenem resistant strains is downgraded.